We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Lung Cancer
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
paola antonelli
Mar 27, 2021
ICI in EGFR mutant NSCLC are not recomended. If possibile I'd choose an EGFR TKI, like Osimertinib (as in adjuvant setting)
Jean-Yves Douillard
Apr 06, 2021
Standard of care for locally advanced unresectable NSCLC has recently changed with the addition of Durvalumab post treatment with concurrent chemoradiation. In the present case above, the patient however has an L858R EGFR mutation. In the Pacific trials, these patients were eligible but represent only 34/709 patients in total. According to the latest updated (early 2021) Forest plot, EGFR mutated patient do not be benefit from consolidation with Durvalumab on OS (HR 0.97; 0.40-2.33), and cannot be recommended
The use of adjuvant Osimertinib as consolidation in the setting of Stage IIIB post chemoradiation is less documented. Trials evaluating Osimertinib post resection have shown a benefit in DFS but there is no proof of an OS benefit.
The risk/benefit of consolidation has not been evaluated. Toxicity and Quality of life have to be considered in patients potentially cured after chemoradiation.
Prognostic biomarkers are needed to potentially help treatment decision, in that instance circulating tumour DNA (ctDNA) could be used and if ctDNA is detected, Osimertinib could be prescribed and its efficacy measured of repeated ctDNA testing.
If not, I would personally opt for an imaging surveillance or look for a clinical trial addressing the question.
GALA NAUSICAA ROMERO MORATALLA
Nov 18, 2021
EGFR L858R mutation was positive
Now I think she must treament with TKI inhibitor (Osimertinib) before anti PD- 1 treatment by Guidelines
GALA NAUSICAA ROMERO MORATALLA
Nov 18, 2021
EGFR L858R mutation was positive
Now I think she must treament with TKI inhibitor (Osimertinib) before anti PD- 1 treatment by Guidelines
Apr 19, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Michael
J.
Grant
MD
paola antonelli
Mar 27, 2021
Jean-Yves Douillard
Apr 06, 2021
GALA NAUSICAA ROMERO MORATALLA
Nov 18, 2021
GALA NAUSICAA ROMERO MORATALLA
Nov 18, 2021
Apr 19, 2024
Pending Moderator approval.